HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effective oncolytic vaccinia therapy for human sarcomas.

AbstractBACKGROUND:
Approximately one fourth of bone and soft-tissue sarcomas recur after prior treatment. GLV-1h68 is a recombinant, replication-competent vaccinia virus that has been shown to have oncolytic effects against many human cancer types. We sought to determine whether GLV-1h68 could selectively target and lyse a panel of human bone and soft-tissue sarcoma cell lines in vitro and in vivo.
METHODS:
GLV-1h68 was tested in a panel of four cell lines including: fibrosarcoma HT-1080, osteosarcoma U-2OS, fibrohistiocytoma M-805, and rhabdomyosarcoma HTB-82. Gene expression, infectivity, viral proliferation, and cytotoxicity were characterized in vitro. HT-1080 xenograft flank tumors grown in vivo were injected intratumorally with a single dose of GLV-1h68.
RESULTS:
All four cell lines supported robust viral transgene expression in vitro. At a multiplicity of infection (MOI) of five, GLV-1h68 was cytotoxic to three cell lines, resulting in >80% cytotoxicity over 7 d. In vivo, a single injection of GLV-1h68 into HT-1080 xenografts exhibited localized intratumoral luciferase activity peaking at d 2-4, with gradual resolution over 8 d and no evidence of spread to normal tissues. Treated animals exhibited near-complete tumor regression over a 28-d period without observed toxicity.
CONCLUSION:
GLV-1h68 has potent direct oncolytic effects against human sarcoma in vitro and in vivo. Recombinant vaccinia oncolytic virotherapy could provide a new platform for the treatment of patients with bone and soft tissue sarcomas. Future clinical trials investigating oncolytic vaccinia as a therapy for sarcomas are warranted.
AuthorsShuangba He, Pingdong Li, Chun-Hao Chen, Richard L Bakst, Natalya Chernichenko, Yong A Yu, Nanhai Chen, Aladar A Szalay, Zhenkun Yu, Yuman Fong, Richard J Wong
JournalThe Journal of surgical research (J Surg Res) Vol. 175 Issue 2 Pg. e53-60 (Jun 15 2012) ISSN: 1095-8673 [Electronic] United States
PMID22341347 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Cancer Vaccines
Topics
  • Animals
  • Bone Neoplasms (drug therapy, pathology)
  • Cancer Vaccines (therapeutic use)
  • Cell Line, Tumor
  • Fibrosarcoma (drug therapy, pathology)
  • Histiocytoma, Malignant Fibrous (drug therapy, pathology)
  • Humans
  • In Vitro Techniques
  • Male
  • Mice
  • Mice, Nude
  • Oncolytic Virotherapy
  • Osteosarcoma (drug therapy, pathology)
  • Rhabdomyosarcoma (drug therapy, pathology)
  • Sarcoma (drug therapy, pathology)
  • Soft Tissue Neoplasms (drug therapy, pathology)
  • Treatment Outcome
  • Vaccinia virus
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: